To Evaluate the Pharmacokinetic Interactions and Safety Between Fimasartan and Rosuvastatin

NCT ID: NCT01921946

Last Updated: 2013-10-22

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 50 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-08-31
• Study Completion Date: 2013-10-31

Brief Summary

A phase Ⅰ study to evaluate the pharmacokinetic interactions and safety between fimasartan and rosuvastatin in healthy male volunteers.

Detailed Description

After subjects have signed informed consent voluntarily, they go through screening period for within 21 days.

As period I, subjects of Part A take fimasartan for 7 days and subjects of Part B take rosuvastatin for 7 days.

And then, after wash out for 7 days, as period II, subjects of both Part A and B take fimasartan and rosuvastatin for 7 days.

At each period, subjects of Part A have blood sampling 2nd, 4th, 6th day before medication, 7th day before and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48hour after medication(17 times in each period, 34 times in total).

At each period, subjects of Part B have blood sampling 2nd, 4th, 6th day before medication, 7th day before and 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 8, 12, 24, 48 and 72hour after medication(17 times in each period, 34 times in total).

Conditions

Hypertension

Keywords

Fimasartan

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: CROSSOVER
• Blinding Strategy: NONE

Study Groups

Part A

Fimasartan (7 days) → Fimasartan + Rosuvastatin (7 days)

Group Type: OTHER

Fimasartan

Intervention Type: DRUG

Rosuvastatin

Intervention Type: DRUG

Part B

Rosuvastatin (7 days) → Fimasartan + Rosuvastatin (7 days)

Group Type: OTHER

Fimasartan

Intervention Type: DRUG

Rosuvastatin

Intervention Type: DRUG

Interventions

Fimasartan

Intervention Type: DRUG

Rosuvastatin

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Healthy male subject, aged 20- 55 years at screening.

2. Body weight of ≥ 50 kg and within ± 20% of ideal body weight (IBW)(kg) = {height (cm) - 100} * 0.9

3. No abnormal symptom or sign, based on medical history and physical examination, with no congenital or chronic disease that requires treatment

4. Subject that is considered appropriate for participating in the study by an investigator, based on clinical laboratory test (serology, hematology, clinical chemistry, urinalysis) and ECG, performed within 3 weeks prior to administration of study drug

5. Subjects must be able to listen to and understand the detailed statement of informed consent, and willing to decide to participate in the study, follow the study directions and provide written informed consent

Exclusion Criteria

1. History of clinically significant hypersensitivity to study drug, any other drug or additives (yellow no.5).

2. History of any illness that may affect the absorption, distribution, metabolism or excretion (hepatobiliary, renal, cardiovascular, endocrine (e.g., hypothyroidism), respiratory, gastrointestinal, hemato-oncology, central nervous system, psychiatric and musculoskeletal system)

3. Hypotension (systolic ≤ 100 mmHg or diastolic ≤ 65 mmHg) or hypertension (systolic ≥ 140 mmHg or diastolic ≥ 90 mmHg), measured at screening

4. Active liver disease, or the levels of ALT(Aspartate Transaminase), AST (Alanin Transaminase) or total bilirubin > 1.5 x the upper limit of normal

5. Creatinine clearance < 80 mL/min (calculated by Cockcroft-Gault formula using serum creatinine)

6. Evidence of hereditary disease, including galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.

7. History of gastrointestinal disease (i.g., Crohn's disease, active peptic ulcer) or resection operation that may affect the absorption of the study drug (excluding simple appendectomy or herniorrhaphy)

8. History of major injury, surgical operation, or suspected symptom of acute illness (severe infection, trauma, diarrhea or vomiting) within 4 weeks prior to the first administration of study drug

9. History of excessive alcohol abuse (>21 units/week, 1 unit=10g=12.5mL of pure alcohol), or subjects who cannot abstain from drinking for at least 3 days prior to the start of this study and throughout the study period, or excessive smoking (>10 cigarettes/day)

10. Use of any prescribed drugs or herbal remedies within 2 weeks, or use of any over-the-counter medication within 1 week prior to the first administration of study drug, and this will affect this study or the safety of the subjects in the opinion of the investigator

11. Participation in any other study within 3 months prior to the first administration of study drug (The finish time of previous study is the day of the last administration of study drug)

12. Donation of whole blood within 2 months prior to the first administration of study drug, or donation of any blood products within 1 month prior to the first administration of study drug

13. Abnormal diet that may affect absorption, distribution, metabolism and excretion of drugs (*e.g., Grapefruit juice ≥ 1L /day within 7 days prior to administration of study drug)

14. Positive serologic tests (HBsAg, HCV Ab, HIV Ag/Ab, VDRL)

15. Subject that is judged inappropriate for participating in the study by an investigator, based on clinical laboratory test (serology, hematology, clinical chemistry, urinalysis) or any other reason

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

Kyungpook National University Hospital

OTHER

Sponsor Role: collaborator

Boryung Pharmaceutical Co., Ltd

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Young Ran Yoon, M.D., Ph.D.

Role: PRINCIPAL_INVESTIGATOR

Kyungpook National University Hospital

Locations

Kyungpook National University Hospital

Daegu, , South Korea

Countries

South Korea

Other Identifiers

BR-FMS-CT-116

Identifier Type: -

Identifier Source: org_study_id